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Abstract
Background Despite many publications reporting on the
increased hospital cost of robotic-assisted surgery (RAS)
compared to direct manual laparoscopic surgery (DMLS)
and open surgery (OS), the reported health economic
studies lack details on clinical outcome, precluding valid
health technology assessment (HTA).
Methods The present prospective study reports total cost
analysis on 699 patients undergoing general surgical,
gynecological and thoracic operations between 2011 and
2014 in the Italian Public Health Service, during which
period eight major teaching hospitals treated the patients.
The study compared total healthcare costs of RAS, DMLS
and OS based on prospectively collected data on patient
outcome in addition to healthcare costs incurred by the
three approaches.
Results The cost of RAS operations was significantly
higher than that of OS and DMLS for both gynecological
and thoracic operations (p\ 0.001). The study showed no
significant difference in total costs between OS and DMLS.
Total costs of general surgery RAS were significantly
higher than those of OS (p\ 0.001), but not against DMLS
general surgery. Indirect costs were significantly lower in
RAS compared to both DMLS general surgery and OS
gynecological surgery due to the shorter length of hospital
stay of RAS approach (p\ 0.001). Additionally, in all
specialties compared to OS, patients treated by RAS
experienced a quicker recovery and significantly less pain
during the hospitalization and after discharge.
Conclusions The present HTA while confirming higher
total healthcare costs for RAS operations identified sig-
nificant clinical benefits which may justify the increased
expenditure incurred by this approach.
Keywords Health technology assessment  Robotic
surgery  da Vinci  Economic evaluation in health care 
Economics of innovation
Since 2000, the da Vinci surgical robot (Intuitive Surgical)
has been the only system used clinically as an alternative to
DMLS for the vast majority of laparoscopic operations. In
2013, surgeons performed approximately 523,000 robotic
procedures worldwide, the commonest being hysterectomy
and prostatectomy [1]. RAS has several advantages over
DMLS, as the wristed end effectors permit seven degrees
of freedom, thereby overcoming the kinematic constraints
of DMLS, which together with motion scaling and HD
stereoscopic imaging facilitates the execution of
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laparoscopic operations. One of the barriers to widespread
adoption of this technology is its high capital, running and
maintenance costs [2]. Health technology assessment
(HTA) is a multidisciplinary evaluation of the clinical,
economical, organizational and ethical implications con-
cerning the adoption of new technologies, designed to
provide healthcare providers with the relevant information
necessary for informed decisions [3–6]. Although ideally
performed when new and expensive technologies are first
introduced, such an HTA has not been reported.
Materials and methods
Study design
The study enrolled patients from four regions (Lombardy,
Piedmont, Tuscany and Lazio) by eight Italian major aca-
demic teaching hospitals during the period from February
2011 to May 2014 (details in appendix). The study as
designed fulfilled all the required criteria of a HTA com-
parative study: prospectively collected non-randomized
data on all consecutively enrolled patients, detailed anal-
ysis of costs of treatment from admission to 1 week after
discharge, and evidence that clinical outcome was not
demonstrably jeopardized by any of the three approaches
used. The decision on the surgical approach was made by
the attending physician in consultation with the patient. A
case study form designed specifically for the collection of
both clinical and health economic data was used. It com-
prised the following sections: enrollment/admission (T0);
first follow-up (T1) 1 month after discharge; subsequent
follow-ups (T3, T4, T6) at 3, 4, 6 months. An additional
form was used for data from patients needing re-interven-
tion during hospitalization or re-admission within 30 days
of discharge.
A Web-based ad hoc database was developed for data
collection using EasyPHP to create dynamic Web pages for
data access and analysis. Patients’ confidentiality was by
data anonymization using an alphanumeric univocal code.
Each participating hospital identified a data manager, who
accessed the data collection platform by username and
password. Knowledge Discovery in Data process was
implemented by different software and programming lan-
guages for automation of the data collection, extraction and
analysis.
Clinical assessment
The T0 stage included admission, operation, and postop-
erative course, including any postoperative re-intervention.
It collected data on:
1. operating time (min) defined as interval between entry
and exit of patient from the operative room (OR);
2. length of stay (days) including any re-admissions;
3. pain level diary by visual linear analogue scale from
admission until 7 days post-discharge;
4. conversions classified as ‘enforced’ and ‘elective,’
using accepted definitions;
5. morbidity;
6. deaths including those following re-admission.
Assessment of health costs
Direct healthcare costs were obtained by interviews con-
ducted with an official from the Accounting Department of
the hospitals involved in the study. It included the hourly
cost of all staff working in the OR, daily cost of stay in
wards and intensive care units; purchase cost of disposables
and devices; and retail price per unit dose of drugs used [7].
Costs of laboratory tests, instrumental investigations and
specialist visits were based on National Tariffs List of
Outpatient Specialist Care of the four regions [8–11].
Direct non-healthcare costs were estimated using the
replacement value [12] and includeddata onpatient’s and care
provider’s expenditure on food, accommodation and trans-
port. Indirect costs based on loss of productivity were calcu-
lated using the human capital approach [13]. Specifically,
productivity losseswere estimated frompatient’s hospital stay
and expected income and employment. Currency conversions
fromEuros toUS dollars (€1 = $1.112) were calculated as of
May 21, 2015 (http://www.oanda.com/lang/it).
Statistical analysis
Pearson Chi-square and Fisher’s exact tests were used to
compare frequencies among groups. Continuous variables
were analyzed by analysis of variance, or by nonparametric
Kruskal–Wallis test depending on distribution of the data.
Bonferroni post hoc tests or Mann–Whitney test with
Bonferroni adjustment of p value was used for post hoc
comparisons. Mixed-effects ML regression models for
repeated measures were used to evaluate the level of pain
during hospitalization and at home. Separated models were
performed for each specialty. Variables with p value
\0.001 on univariate analysis were included in the mul-
tivariate analysis. Statistical significance was set at 5 %.
Results
The study recruited 699 patients who underwent operations
in general surgery (n = 310), gynecology (n = 175) and
thoracic surgery (n = 214) (Table 1).
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Socio-demographic details
Of the 310 patientswho underwent general surgical operations,
161 (52 %)underwentRAS, 113 (36 %)DMLSand36 (12 %)
OS. The characteristics of the groups differed. Thus, patients
treated by OS were more likely to be male (p\0.001).
Additionally, patients undergoing RAS were significantly
younger (60 ± 15 years) with respect to DMLS (65 ±
14 years) and OS (72 ± 8 years) (p\0.001). The employ-
ment status of the patients also differed (p = 0.002): the
majority of patients treated by OS were retired (78 %), while
37 % of the patients who underwent RAS were employed.
Table 1 Patients enrolled per
center, surgical technique and
type of intervention
Surgical specialty Type of intervention RAS DMLS OS Total
University Hospital of Pisa
Thoracic surgery Pulmonary lobectomy 36 0 22 58
Thymectomy 9 0 8 17
Gynecological surgery Hysterectomy for benign disease 34 18 18 70
Hysterectomy for carcinoma 21 1 2 24
Radical hysterectomy 8 0 6 14
Myomectomy 31 12 23 66
Removal of uterus 1 0 0 1
Pelvis endometriosis 1 0 0 1
General surgery Pancreatectomy 1 0 0 1
Radical prostatectomy 17 0 17 34
Cholecystectomy 0 1 0 1
Hemicolectomy 0 0 1 1
Anterior resection of rectum 0 1 1 2
Adrenalectomy 2 0 0 2
Total per Center 162 33 98 293
Hospital of Alessandria
General surgery Anterior resection of rectum 32 0 0 32
Hospital of Arezzo
General surgery Anterior resection of rectum 12 9 3 24
Campus Biomedico of Roma
General surgery Anterior resection of rectum 11 9 0 20
Abdomino-perineal resection 0 1 0 1
Hemicolectomy 3 2 1 6
Total per Center 14 12 1 27
Hospital of Grosseto
General surgery Anterior resection of rectum 13 12 4 29
European Oncology Institute of Milano
Thoracic surgery Pulmonary lobectomy 20 34 46 100
Thymectomy 0 0 6 6
Pneumonectomy 2 0 2 4
Segmentectomy 8 2 16 26
Wedge 0 2 0 2
Chest wall 1 0 0 1
Total per Center 31 38 70 139
Le Molinette University Hospital of Torino
General surgery Anterior resection of rectum 0 45 1 46
Gastric bypass 56 33 1 80
Radical prostatectomy 0 0 7 7
Total per Center 56 78 9 143
San Matteo University Hospital of Pavia
General surgery Cholecystectomy 0 0 12 12
Total 332 182 185 699
Surg Endosc (2017) 31:543–551 545
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The approach in patients undergoing gynecological opera-
tions was 95 (54 %) by RAS, 31 (18 %) by DMLS and 49
(28 %) by OS. The mean age varied significantly (p = 0.01),
with those treated by OS being significantly younger
(47 ± 11 years) than those operated byRAS (54 ± 13 years).
The approach in patients requiring thoracic surgery was
100 (47 %) by OS, 76 (36 %) by RAS and 38 (18 %) by
DMLS. No significant differences among the groups were
found in the gender distribution, but the mean age was sig-
nificantly lower (p = 0.01) in the RAS group, 64 ± 11 years,
compared to both theDMLSgroup (69 ± 7 years) and theOS
group (67 ± 11). The employment status was different
(p = 0.008) with the highest proportion of retired patients
being in the DMLS (74 %), whereas patients treated by RAS
were more likely to be employed (41 %).
Clinical results and outcome
In general surgery, the hospital stay was significantly
shorter in the RAS compared with DMLS and OS
(p\ 0.001). In gynecological surgery, the hospital stay
was significantly shorter in the RAS versus OS
(p\ 0.001), but not against DMLS. Likewise, the hospital
stay after thoracic surgery was significantly shorter in RAS
compared to the OS group (p\ 0.001), but not against
DMLS. Additionally, in both gynecological and thoracic
surgery, the hospital stay was significantly shorter after
DMLS compared with OS (p\ 0.001). The operating time
was significantly longer in both RAS general and thoracic
surgery compared to OS and DMLS (p\ 0.001 and
p = 0.03, respectively). In gynecological surgery, there
were no significant differences in operating times between
the groups (Table 2).
Conversions, re-interventions and re-admissions
Total conversions during T0 phase were 22: 10 in RAS and
12 in DMLS operations. In general surgery, the 18 con-
versions consisted of 6 in RAS (3 to DMLS, 3 to OS) and
12 in DMLS (12 to OS—10 elective and 2 enforced). In
gynecology, there was one elective conversion from RAS
to DMLS. In thoracic surgery, two out of three conversions
to OS were enforced and the third, elective. One elective
conversion occurred during a re-intervention in T0 in RAS
general surgery to OS (see Appendix Table A1).
Nine patients required re-intervention during T0 phase: 5
in DMLS general surgery, 2 after RAS. Two other patients
required re-intervention in thoracic surgery: 1 after OS and
another after RAS (see Appendix Table A2).
Eight patients required re-admissions within 30 days of
discharge from hospital: 4 in general surgery, of which 1
after RAS, 2 after DMLS and 1 after OS. The two re-
admissions in gynecology occurred after DMLS and OS. In
thoracic surgery, two patients were re-admitted: 1 each
after RAS and OS. These differences between the three
approaches were not significant (see Appendix Table A3).
Intraoperative complications
These were encountered during 16 operations, being minor
in 6 and major in 10. Minor complications occurred in
general (1 DMLS and 2 RAS) and in thoracic surgery (all 3
OS). None altered the surgical treatment or subsequent
clinical course. Major complications were encountered in
all three specialties: 1 during RAS general surgery, 5
during gynecological operations (2 RAS and 3 OS) and 4
thoracic (2 RAS and 2 OS), again without significant dif-
ferences between the groups (see Appendix Table A4).
Postoperative morbidity
Total postoperative morbidity comprised 17 minor and 35
major complications. The former were largely encountered
in general surgery (4 after DMLS, 3 after OS and 6 after
RAS), 1 after gynecological DMLS and 3 after open tho-
racic surgery. Major complications were encountered in
general surgery (n = 19) and thoracic surgery (n = 16).
The major complications after general surgery operations
were encountered in 10 after RAS, 7 after DMLS and 2
after OS. The distribution of major complications after
thoracic operations (9 after RAS, 6 after OS and 1 after
DMLS) was similar (see Appendix Table A5).
There were 54 medical postoperative complications: 22
in general surgery (9 in RAS, 8 after DMLS and 5 after
OS), 1 in gynecology after DMLS and 31 after thoracic
surgery (18 after OS, 11 in RAS and 2 after DMLS). The
incidence of medical complications was similar between
the groups (see Appendix Table A6).
Clinical benefits documented by present study
The most significant benefit of RAS operations across the
three specialties was the reduced pain after surgery com-
pared to OS and DMLS (Table 3).
Pain during hospitalization
In general surgery, patients treated by RAS experienced
less pain compared to OS (p = 0.026), with the pain level
being similar to that experienced by DMLS patients. On
adjusting for length of stay, the pain level was significantly
lower in gynecological RAS versus both DMLS
(p = 0.032) and OS (p\ 0.001). On adjusting for pain
after discharge, the pain level was significantly lower in
thoracic RAS compared to DMLS (p = 0.002), but not
against OS.
546 Surg Endosc (2017) 31:543–551
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Pain after discharge
The pain level after discharge was significantly lower in
general RAS patients compared to OS (p = 0.001), but not
against DMLS. After gynecological RAS, patients experi-
enced less pain compared to both DMLS (p = 0.027) and
OS (p = 0.001). After thoracic RAS, the pain level was
significantly lower compared to DMLS (p = 0.007), but
not with patients after OS.
Almost all patients undergoing RAS and DMLS in
general and gynecological surgery reported their ability for
daily activities and exercises to be good, very good or
excellent, significantly better than after OS (p = 0.001 and
p\ 0.001, respectively). Hence, their quality of life was
better during this post-discharge period.
Cost analysis
In the gynecological and thoracic specialties, the RAS
approach incurred significantly higher direct healthcare
costs compared to both DMLS and OS (p\ 0.001), while
costs between OS and DMLS were similar. In general
surgery, direct healthcare costs of RAS were higher than
those of OS (p\ 0.001) but similar to those incurred by
DMLS. General surgery performed by the open approach
incurred higher direct healthcare costs compared to DMLS
operations (p\ 0.001).
In general surgery, direct non-healthcare costs were
similar between the three approaches, whereas in gyne-
cology, the RAS approach incurred significantly higher
costs compared to DMLS (p = 0.01). In thoracic surgery,
direct non-healthcare costs were higher for DMLS com-
pared to RAS (p = 0.003) and OS (p = 0.006).
The only significant differences in indirect costs were
observed in general and gynecological surgery. In general
surgery, RAS indirect costs were lower than those of
DMLS (p\ 0.05), whereas in gynecology, RAS indirect
costs were lower than those of OS (p\ 0.001).
Total costs of RAS were significantly higher than those
of the two other approaches for gynecological and thoracic
specialties (p\ 0.001), but total costs for both OS and
DMLS operations were similar. In general surgery, total
costs of RAS were higher compared to OS (p\ 0.001), but
not against DMLS. Full details of the cost analysis data are
shown in Table 4. After adjusting for centers and/or
Table 2 Clinical outcome:
length of hospital stay and
operating time
Specialty/technique Median [25–75 %] p value
RAS versus DMLS
p value
RAS versus OS
Length of stay (days)
General (n = 310)
RAS (n = 161) 6.0 [5.0–8.0] p\ 0.001 p\ 0.001
DMLS (n = 113) 8.0 [6.00–12.0]
OS (n = 36) 8.5 [7.00–10.0]
Gynecological (n = 175)
RAS (n = 95) 3.0 [2.0–3.0] p = 0.17 p\ 0.001
DMLS (n = 31) 3.0 [3.0–4.0]
OS (n = 49) 4.0 [4.0–6.0]
Thoracic (n = 214)
RAS (n = 76) 6.0 [5.0–7.0] p = 0.87 p\ 0.001
DMLS (n = 38) 6.0 [5.0–7.0]
OS (n = 100) 7.0 [6.0–9.0]
Operating time (min)
General
RAS 380.0 [335.0–430.0] p\ 0.001 p\ 0.001
DMLS 285.0 [240.0-345.0]
OS 257.5 [225.0–300.0]
Gynecological
RAS 210.0 [170.0–260.00] p = 0.52 p = 0.11
DMLS 180.0 [145.0–225.0]
OS 185.0 [145.0–230.0]
Thoracic
RAS 299.5 [248.5–359.5] p = 0.03 p\ 0.001
DMLS 266.0 [232.0–310.0]
OS 224.5 [181.0–261.0]
Surg Endosc (2017) 31:543–551 547
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patients characteristics for both direct healthcare costs and
overall costs, the RAS approach incurred significantly
higher costs (Table 5).
Discussion
As required by HTA, the present prospective comparative
study collected data on clinical outcome in addition to health
economic costs. The study was necessary as the HTA ques-
tion: does RAS represent good value for money? has not been
answered; especially as fromthe healthproviders’ and societal
perspectives, the issue is not simply that RAS is more
expensive, but rather—is the extra cost of RAS justified by
improved patient outcome? The present study answers, to a
limited extent, the second question. Thus, while confirming
higher direct healthcare costs (but not direct non-medical and
indirect health costs), it documents that RAS reduces hospital
stay and pain before and after discharge. The pain reported by
patients after discharge associated with essential daily activ-
ities during the first week enhances the quality of life during
this period. An additional benefit of RAS is reduced hospital
stay with a trend toward accelerated recovery leading to less
pain and improved quality of life during the first post-dis-
charge week, ranging from good to excellent.
The alleged benefit of RAS is based on retrospective
studies and mixed systemic reviews/meta-analysis. It is not
surprising that retrospective studies often produce con-
flicting results, due to the influence of uncontrolled vari-
ables. This is exemplified by distal pancreatectomy. In one
study which compared DMLS with RAS for distal pan-
createctomy for tumors, spleen-preserving RAS was
Table 3 Pain level: mixed-effects ML regression models for repe-
ated measures
Coeff. 95 % CI p value
Pain during hospitalization
General surgery
Unadjusted
RAS Ref. – –
DMLS 0.023 -0.105 to 0.150 0.726
OS 0.243 0.035–0.451 0.022
Adjusteda
RAS Ref. – –
DMLS -0.036 -0.161 to 0.088 0.564
OS 0.227 0.027–0.427 0.026
Gynecological surgery
Unadjusted
RAS Ref. – –
DMLS 0.331 0.572–0.605 0.018
OS 0.518 0.295–0.740 \0.001
Adjustedb
RAS Ref. – –
DMLS 0.299 0.026–0.572 0.032
OS 0.428 0.187–0.668 \0.001
Thoracic surgery
Unadjusted
RAS Ref. – –
DMLS 0.417 0.188–0.647 \0.001
OS -0.005 -0.185 to 0.175 0.957
Adjustedc
RAS Ref. – –
DMLS 0.312 0.114–0.511 0.002
OS -0.023 -0.178 to 0.132 0.768
Pain after discharge
General surgery
Unadjusted
RAS Ref. – –
DMLS 0.004 -0.095 to 0.102 0.943
OS 0.343 0.178–0.508 \0.001
Adjustedd
RAS Ref. – –
DMLS -0.046 -0.141 to 0.049 0.341
OS 0.255 0.098–0.412 0.001
Gynecological surgery
Unadjusted
RAS Ref. – –
DMLS 0.333 0.128–0.537 0.001
OS 0.539 0.365–0.713 \0.001
Adjustede
RAS Ref. – –
DMLS 0.221 0.025–0.417 0.027
OS 0.275 0.110–0.440 0.001
Table 3 continued
Coeff. 95 % CI p value
Thoracic surgery
Unadjusted
RAS Ref. – –
DMLS 0.352 0.134–0.570 0.002
OS 0.104 -0.065 to 0.273 0.229
Adjustedf
RAS Ref. – –
DMLS 0.259 0.070–0.448 0.007
OS 0.104 -0.042 to 0.250 0.164
a Adjusted model for length of stay and conversions
b Adjusted model for length of stay
c Adjusted model for pain at home
d Adjusted model for pain during hospitalization and conversions
e Adjusted model for pain during hospitalization and age
f Adjusted model for pain during hospitalization, postoperative
complications and re-interventions
548 Surg Endosc (2017) 31:543–551
123
Table 4 Costs associated with the different surgical approaches by specialty
Technique Median [25–75 %] p value
€ $ RAS versus DMLS RAS versus OS
General surgery (n = 310)
Total direct healthcare costs
RAS 9928 [9158–10,893] 11,038 [10,181–12,110] p = 0.52 p\ 0.001
DMLS 9997 [7322–11,095] 11,114 [8140–12,335]
OS 6764 [6084–8131] 7520 [6764–9040]
Total direct non-healthcare costs
RAS 585 [340–922] 650 [378–1025] p = 0.94 p = 0.44
DMLS 564 [399–878] 627 [443–976]
OS 516 [368–889] 574 [409–988]
Indirect costs
RAS 1064 [649–1313] 1183 [721–1460] p = 0.02 p = 0.28
DMLS 1313 [1021–1525] 1460 [1135–1695]
OS 1275 [1034–1543] 1417 [1150–1715]
Total costs
RAS 10,822 [9995–12,065] 12,031 [11,112–13,413] p = 0.35 p\ 0.001
DMLS 10,778 [8660–12,242] 11,983 [9628–13,610]
OS 7267 [6613–8684] 8079 [7352–9655]
Gynecological surgery (n = 175)
Total direct healthcare costs
RAS 7902 [7507–8499] 8785 [8346–9449] p\ 0.001 p\ 0.001
DMLS 4231 [3878–5129] 4704 [4311–5702]
OS 4328 [3768–5610] 4812 [4189–6237]
Total direct non-healthcare costs
RAS 351 [281–523] 390 [312–581] p = 0.01 p = 0.76
DMLS 281 [210–381] 312 [233–423]
OS 341 [260–590] 379 [289–656]
Indirect costs
RAS 683 [502–859] 759 [558–955] p = 0.38 p\ 0.001
DMLS 739 [515–859] 821 [572–955]
OS 964 [749–1202] 1072 [833–1336]
Total costs
RAS 8739 [8110–9757] 9716 [9016–10,847] p\ 0.001 p\ 0.001
DMLS 4936 [4733–6249] 5488 [5262–6947]
OS 5753 [4609–8378] 6396 [5124–9314]
Thoracic surgery (n = 214)
Total direct healthcare costs
RAS 11,917 [10,676–13,095] 13,249 [11,869–14,558] p\ 0.001 p\ 0.001
DMLS 8887 [7738–9839] 9880 [8603–10,939]
OS 8884 [7824–9878] 9877 [8698–10,982]
Total direct non-healthcare costs
RAS 987 [595–1450] 1097 [661–1612] p = 0.003 p = 0.32
DMLS 2065 [801–3655] 2296 [890–4063]
OS 1043 [702–1626] 1160 [780–1808]
Indirect costs
RAS 1202 [1053–2363] 1336 [1171–2627] p = 0.28 p = 1.00
DMLS 1153 [886–1520] 1282 [985–1690]
OS 1342 [1114–1564] 1492 [1239–1739]
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associated with significantly higher spleen preservation
rates, shorter operating time, less blood loss and shorter
mean hospital stay [14]. However, a similar but prospective
non-randomized study did not report any significant dif-
ference. Depending on availability of robot, all patients
suitable for distal pancreatectomy were assigned either to
DMLS or to RAS DP. The median operative time was
longer, and procedures cost was double in RAS group.
Conversion to open and the median length of postoperative
hospital stay were similar, as was pancreatic fistula rate (57
and 50 %) [15]. In colorectal surgery, a meta-analysis on
RAS total mesorectal resection for rectal cancer compared
DMLS-TME with RAS-TME. The latter exhibited signifi-
cantly fewer conversions, lower positive circumferential
resection margins, and erectile dysfunction [16]. Thus for
this operation, RAS appears to carry clinical benefit over
DMLS, despite increased cost.
Two publications in gynecology on health-related
quality of life [17, 18] reported results in favor of RAS,
which are in agreement with the results of the present
prospective HTA study. The first [17] used a HRQoL
questionnaire to study patient satisfaction in patients
undergoing RAS hysterectomy for cancer. The HRQoL
questionnaire was completed at the first postoperative visit
in 109 patients. These reported the pain level as being
highest on the second postoperative day, but two-thirds
reported no pain by the first postoperative visit, and only
18 % of patients needed narcotics for pain control. Most
patients resumed normal activities within 11 days after
surgery and reported a satisfaction rating of 6.7 on a
7-point scale. The other report [18] studied the HRQoL in
211 patients also undergoing RAS resection of gynecologic
cancer. The patients completed a QoL questionnaire before
surgery and postoperatively at 1 and 3 weeks, and at 3, 6
Table 4 continued
Technique Median [25–75 %] p value
€ $ RAS versus DMLS RAS versus OS
Total costs
RAS 13,856 [12,343–15,291] 15,405 [13,722–17,000] p\ 0.001 p\ 0.001
DMLS 10,888 [9178–13,357] 12,105 [10,204–14,850]
OS 10,574 [9188–11,737] 11,756 [10,215–13,049]
Table 5 Adjusted costs
differences by specialty
Specialty/technique Coeff. SE p value Inf. 95 % Sup. 95 %
Total direct healthcare costs
Generala
DMLS versus RAS -1256.472 424.2759 0.003 -2088.037 -424.9067
OS versus RAS -3242.441 458.0922 \0.001 -4140.285 -2344.596
Gynecologicalb
DMLS versus RAS -3256.859 343.91 \0.001 -3930.91 -2582.808
OS versus RAS -2609.776 325.5717 \0.001 -3247.885 -1971.667
Thoracica
DMLS versus RAS -3883.981 534.3085 \0.001 -4931.206 -2836.755
OS versus RAS -3566.99 409.8714 \0.001 -4370.323 -2763.657
Total costs
Generala
DMLS versus RAS -1299.863 466.9079 0.005 -2214.986 -384.7402
OS versus RAS -3542.22 508.8817 \0.001 -4539.61 -2544.83
Gynecologicalb
DMLS versus RAS -3380.546 421.8935 \0.001 -4207.442 -2553.65
OS versus RAS -2248.316 411.214 \0.001 -3054.28 -1442.351
Thoracica
DMLS versus RAS -3775.765 676.8711 \0.001 -5102.408 -2449.122
OS versus RAS -4001.056 499.1097 \0.001 -4979.294 -3022.819
a Adjusted model considering centers’ effects
b Adjusted model for age
550 Surg Endosc (2017) 31:543–551
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and 12 months. Overall HRQoL and body image decreased
at 1 week after surgery but returned to baseline by
3 weeks. Physical and functional well-being decreased at
1 week after surgery but returned to baseline by 3 months.
Another study [19] compared the postoperative pain man-
agement and costs in endometrial cancer patients who
underwent a RAS hysterectomy. In this study, RAS
patients needed a lower number of drug interventions
(p\ 0.001), with a 50 % reduction in the pain medication
costs on the day of surgery (p\ 0.01), and a 56 % cost
reduction for the rest of their hospital stay (p\ 0.01). The
pain reduction demonstrated by this retrospective study is
confirmed by the present prospective HTA study. A large
statewide health economic study involving 2247 patients
analyzed the utilization and hospital charges associated
with RAS versus DMLS and OS treatment of endometrial
cancer [20]. In this study, 29 % of patients were treated by
RAS, 10 % by DMLS and 61 % by OS. The mean length
of hospital stay was significantly shorter after RAS and
DMLS compared to OS (p\ 0.001). The median hospital
charge was $51,569, $37,202 and $36,492, for RS, LS and
OS (p\ 0.001). A recent report in thoracic surgery is
relevant to the present HTA study. The study was designed
to determine a realistic medical fee for RAS thoracic sur-
gery for the Japanese National Health Insurance System
(JNHIS) introduced in 2012 [21]. It concluded that the
projected cost to the JNHIS for RAS thoracic interventions
would only be sustainable by institutions, which performed
more than 300 RAS interventions per year.
In conclusion, the present HTA study indicates that the
issue of increased costs of RAS is complex and multifac-
torial. RAS is likely to be cost beneficial in terms of
reduced hospital stay, reduced pain and improved quality
of life, provided certain conditions are met, including case
load and case mix.
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